Carisma Therapeutics Inc. (CARM): Nasdaq/NYSE listing notice — Carisma Therapeutics to be delisted from Nasdaq on Oct 13; expects to wind down operations

Carisma Therapeutics Inc.

Received Nasdaq delisting letter; common stock suspended from trading effective Oct 13, 2025; no appeal planned.
Approval received to list common stock on OTCID market tier under symbol CARM starting Oct 13, 2025.
Company expects to pursue sale or monetization of remaining assets and orderly wind down of operations.
Warns that it is unlikely there will be meaningful cash available for distribution to stockholders.
May file Form 15 to suspend SEC reporting obligations after delisting.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Carisma Therapeutics Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

October 9, 2025, Carisma Therapeutics Inc. (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing Rules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025. The Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities and Exchange Commissio

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-098404

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.